Victoria-based company Immunoprecise Antibodies, appoints Jennifer L. Bath, the chief executive officer and president of ImmunoPrecise, as a member of its board of directors, Charles (Chip) Wheelock as the global chief technology officer and Kari Graber as the director of Global Client Services and Project Management.
“Under Jennifer’s leadership, ImmunoPrecise has evolved into the first full-service discovery antibody CRO in North America and Europe,” comments James Kuo, Chairman of ImmunoPrecise. “Over the last three months, Jennifer oversaw our immediately accretive acquisition of ModiQuest, the addition of our new facility that provides B-cell sorting capabilities and our focus on antibody discovery for therapeutic antibodies. We are extremely supportive of Jennifer’s vision to create a global single source CRO from inception of the target to clinical trials.”
Chip Wheelock, chief technology officer brings a diverse background to IPA, he has held leadership positions within the software development and services industries over the past 25 years encompassing global ERP deployments, cloud transformations and building strategic line of business applications. Wheelock’s experience includes 16 years at Microsoft in various roles, most recently as a senior global technical account manager, where he drove both strategic and technical initiatives for many large organizations. He holds a Bachelor’s degree from the University of Kansas along with several industry and project management certifications.
Kari Graber, director of Global Project Management, has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers and spent five years as sales and technical director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Graber served at Aldevron LLC where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology with a Minor in Microbiology from North Dakota State University.
“The expansion of our senior leadership in the areas of information technology, client services and project management positions IPA to further its growth as a single provider of integrated antibody discovery for therapeutic drug discovery,” says Jennifer L. Bath, president and CEO of IPA. “We believe these positions further equip IPA to fully integrate each of our business units located in North America and Europe to provide a seamless value chain to our clients as IPA expands globally.”